biostudies-literatureUnknown26(1)Verhoeven MAdvanced Accelerator Applications, a Novartis Company<h4>Purpose</h4>Radiolabeled NeoB is a promising gastrin-releasing peptide receptor (GRPR)-targeting radiopharmaceutical for theranostics of GRPR-expressing malignancies, e.g., prostate cancer (PCa). The aim of this study was to evaluate the effect of different doses of [¹⁷⁷Lu]Lu-NeoB on the balance between therapeutic efficacy and safety in a preclinical PCa model.<h4>Procedures</h4>To determine the efficacy of [¹⁷⁷Lu]Lu-NeoB, PC-3 xenografted mice received 3 sham injections (control group) or 3 injections of 30 MBq/300 pmol, 40 MBq/400 pmol, or 60 MBq/600 pmol [¹⁷⁷Lu]Lu-NeoB (groups 1, 2, and 3, respectively) 1 week apart. To quantify tumor uptake, single-photon emission computed tomography/computed tomography (SPECT/CT) imaging was performed 4 h after thMolecular imaging and biology114-123https://www.ebi.ac.uk/biostudies/studies/S-EPMC10828073biostudies-literatureThe Balance Between the Therapeutic Efficacy and Safety of [¹⁷⁷Lu]Lu-NeoB in a Preclinical Prostate Cancer Model.PMC10828073Konijnenberg MBarbato DDalm SUOrlandi FHaeck Jde Blois ETedesco MVerhoeven MfalseThe Balance Between the Therapeutic Efficacy and Safety of [¹⁷⁷Lu]Lu-NeoB in a Preclinical Prostate Cancer Model.<h4>Purpose</h4>Radiolabeled NeoB is a promising gastrin-releasing peptide receptor (GRPR)-targeting radiopharmaceutical for theranostics of GRPR-expressing malignancies, e.g., prostate cancer (PCa). The aim of this study was to evaluate the effect of different doses of [¹⁷⁷Lu]Lu-NeoB on the balance between therapeutic efficacy and safety in a preclinical PCa model.<h4>Procedures</h4>To determine the efficacy of [¹⁷⁷Lu]Lu-NeoB, PC-3 xenografted mice received 3 sham injections (control group) or 3 injections of 30 MBq/300 pmol, 40 MBq/400 pmol, or 60 MBq/600 pmol [¹⁷⁷Lu]Lu-NeoB (groups 1, 2, and 3, respectively) 1 week apart. To quantify tumor uptake, single-photon emission computed tomography/computed tomography (SPECT/CT) imaging was performed 4 h after th2024-01-01T00:00:00Z2024 Feb2025-04-26T19:19:23.114Z2025-04-06T16:05:47.902ZS-EPMC108280733764094110.1007/s11307-023-01851-4